Background: Increased homocysteine levels might accelerate dopaminergic cell death in Parkinson disease (PD), through neurotoxic effects. Higher dietary intakes of folate, vitamin B 12 , and vitamin B 6 (cofactors in homocysteine metabolism) might decrease the risk of PD through decreasing plasma homocysteine. Moreover, vitamin B 6 might influence the risk of PD through antioxidant effects unrelated to homocysteine metabolism and through its role in dopamine synthesis. Methods: In the Rotterdam Study, a prospective, population-based cohort study of people aged 55 years and older, the authors evaluated the association between dietary intake of folate, vitamin B 12 , and vitamin B 6 and the risk of incident PD among 5,289 participants who were free of dementia and parkinsonism and underwent complete dietary assessment at baseline. PD was assessed through repeated in-person examination and continuous monitoring by computer linkage to medical records. Data were analyzed using Cox proportional hazards regression analysis. Results: After a mean follow-up of 9.7 years, the authors identified 72 participants with incident PD. Higher dietary intake of vitamin B 6 was associated with a significantly decreased risk of PD (hazard ratio per SD, 0.69 [95% CI 0.50 to 0.96]; for highest vs lowest tertile, 0.46 [0.22 to 0.96]). Stratified analyses showed that this association was restricted to smokers. No association was observed for dietary folate and vitamin B 12 . Conclusions: Dietary vitamin B 6 may decrease the risk of Parkinson disease, probably through mechanisms unrelated to homocysteine metabolism.
NEUROLOGY 2006;67: [315] [316] [317] [318] The exact mechanisms that underlie the process of degeneration of dopaminergic neurons in Parkinson disease (PD) are unclear, but oxidative stress may play a prominent role. 1, 2 High homocysteine levels might enhance dopaminergic cell death through neurotoxic effects. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal models of PD, brain injections of homocysteine exacerbated dopaminergic cell loss and motor dysfunction. 3 In cultured human dopaminergic neurons, homocysteine was found to increase rotenone-induced oxidative stress and apoptosis. 3, 4 Increased homocysteine levels have been reported in patients with PD but may also have resulted from treatment with levodopa. [5] [6] [7] Prospective studies on the relationship between homocysteine levels and PD risk have not been published thus far, but our group previously found an increased risk of PD in carriers of the hyperhomocystinemic MTHFR 677 TT genotype. 8 Homocysteine levels are kept low by remethylation to methionine, which requires folate and vitamin B 12 , and by conversion to cysteine, for which vitamin B 6 is an essential cofactor. 9 Increased plasma homocysteine levels reportedly are associated with low plasma levels as well as low dietary intakes of folate, vitamin B 12 , and vitamin B 6 . [10] [11] [12] [13] Vitamin B 6 (pyridoxine) might furthermore influence PD risk through antioxidant effects unrelated to homocysteine metabolism [14] [15] [16] [17] [18] [19] and through its role in dopamine synthesis. 20, 21 We hypothesized that higher intakes of folate, vitamin B 12 , and vitamin B 6 might be associated with a decreased risk of PD and studied this association prospectively in 5,289 participants of the populationbased Rotterdam Study.
Methods.
The Rotterdam Study. The Rotterdam Study is a prospective, population-based cohort study among 7,983 persons aged 55 years and older in a district of Rotterdam, The Netherlands. 22 At baseline (1990 -1993) , all participants were interviewed and subsequently underwent extensive physical examination, which included a neurologic screening. Follow-up examinations according to the same protocol took place in 1993-1994, 1997-1999, and 2002-2004 . In addition, the cohort was continuously monitored for major disease outcomes and mortality through computerized linkage of the study database to general practitioners' medical files. Informed consent was obtained from each participant, and the Medical Ethics Committee of the Erasmus Medical Center Rotterdam approved the study.
Assessment of PD.
In all four examination rounds, we used a similar two-phase design to identify subjects with PD. 23 Participants were screened for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia, or impaired postural reflexes) in a standardized way. Persons in whom at least one of these signs was observed were considered screen-positive and received a structural diagnostic workup, comprising the Unified Parkinson's Disease Rating Scale 24 and neurologic examination. Also, a panel of neurologists and research physicians reviewed the information that was obtained from the computerized surveillance system to detect possible new cases of PD. PD was diagnosed if two or more cardinal signs were present in a participant not taking antiparkinsonian drugs, or if at least one sign had improved through medication, and when all causes of secondary parkinsonism (dementia, use of neuroleptics, cerebrovascular disease, multiple system atrophy, or progressive supranuclear palsy) could be excluded.
Assessment of dietary variables and covariates. At baseline, dietary intake was assessed through an interview by a trained dietician, using an extensive, validated semiquantitative foodfrequency questionnaire (SFFQ). 25 The amounts of food and drink intake indicated on the SFFQ were converted to energy intake and nutrient intake by means of the computerized Dutch Food Composition Table. For the current study, we used data on dietary intake of folate (in g/day), vitamin B 12 (in g/day), vitamin B 6 (in mg/day), alcohol (in g/day), coffee (number of cups/day), and total energy (in kcal/day), as well as data on use of B-vitamin and folate supplements.
At baseline, we assessed smoking status during the interview (classified as ever [current or former] or never smoking) and measured intima-media thickness (IMT) of the carotid arteries by ultrasonography as described elsewhere. 26 Study population. Baseline neurologic screening was performed in 6,969 participants, of whom 130 were diagnosed with any parkinsonism, resulting in a cohort at risk to develop PD during follow-up of 6,839 persons. The SFFQ was not administered to participants with dementia at baseline (because they might give unreliable dietary information) or nursing home residents (because their current diet may not reflect dietary habits in the past). Participants with incomplete or inconsistent dietary data were also excluded from the analyses. The study sample for the current study thus comprised 5,289 independently living participants free of dementia and parkinsonism at baseline, for whom complete dietary data were available.
Data analysis. The relation between dietary folate, vitamin B 12 , and vitamin B 6 and the risk of incident PD was analyzed with Cox proportional hazards regression analysis, adjusted for age, sex, and total energy intake, per SD and expressed in tertiles of intake. Because smoking reportedly influences both homocysteine levels 27 and PD risk, 28 analyses were both adjusted for and stratified by smoking status. Additional adjustments were made for intake of alcohol and coffee, being determinants of plasma homocysteine, 27 and for IMT as a measure of atherosclerosis, to evaluate whether vascular mechanisms could explain the results. We reanalyzed the data after exclusion of users of B-vitamin and folate supplements (n ϭ 675), and after adding supplement users to the highest tertile of intake, and examined the effect of supplement use itself on PD risk. We tested for statistical interaction between dietary intake and smoking status by adding multiplicative interaction terms to the model. All analyses were performed using SPSS software, version 12.0.
Results. Follow-up information was available for 99% of the participants, either through in-person examination or through the computerized monitoring system. During a total of 53,262 person-years of follow-up (mean 9.7 years), 72 new cases of PD were identified. Of those, 44 cases were detected through the structured workup at the research center, and 28 were detected through the computerized surveillance system.
In table 1 , baseline characteristics of the study population are presented. Table 2 shows the hazard ratios (HRs) with 95% CIs for the association between dietary folate, vitamin B 12 , and vitamin B 6 and the risk of PD, per SD and in tertiles of intake. Higher intake of vitamin B 6 was associated with a significantly decreased risk of PD (HR per SD, 0.69 [95% CI 0.50 to 0.96], for highest vs lowest tertile 0.46 [0.22 to 0.96]), with evidence for a dose-effect relationship (p value for trend over tertiles, 0.048). No association with PD risk was seen for dietary vitamin B 12 and folate. Results were not substantially different after adjusting for smoking, alcohol intake, coffee consumption, and IMT or when supplement users were excluded or added to the highest tertile. Supplement use itself was not associated with the risk of PD (data not shown). Adding dietary folate, vitamin B 12 , and vitamin B 6 simultaneously to the model for mutual adjustments did not change the effect estimates for vitamin B 6 and B 12 but attenuated the HR for folate intake to 1.04 (95% CI 0.64 to 1.70). Stratified analyses (table 3) showed that higher intake of vitamin B 6 was associated with a decreased risk of PD in smokers (HR per SD, 0.53 [95% CI 0.35 to 0.81]), but not in nonsmokers (HR 0.99 [95% CI 0.58 to 1.68]). The p value for the multiplicative interaction term containing vitamin B 6 intake and smoking was 0.036. Results for vitamin B 12 and folate intake were not different for smokers and nonsmokers.
Discussion. In this prospective, population-based cohort study, we found that higher intake of vitamin B 6 , but not vitamin B 12 or folate, was associated with a significantly decreased risk of PD. Subanalyses suggested that this association was confined to smokers. Methodologic strengths of this study include the extensive case-finding procedures and virtually complete follow-up with a large number of person-years. Moreover, because of the prospective design with dietary assessments before onset of PD, the possibility that changes in intake as a consequence of the disease influenced the results is limited, although not completely excluded. Among the methodologic constraints of our study are the limited statistical power to perform stratified analyses and the possibility of misclassification of nutrient intake inherent to a food frequency questionnaire. Future disease status though was unknown at baseline, and dietary misclassification-if any-therefore most likely did not differ between participants with and without incident PD, causing at most an underesti- mation of the association. Furthermore, dietary intake may not necessarily correspond to actual levels of B vitamins. In particular, for vitamin B 12 , malabsorption in the elderly may lead to low levels even when intake is adequate. A certain degree of uncertainty regarding disease status is unavoidable in epidemiologic studies on PD, because in the absence of an unambiguous test for the disease, the diagnosis is still based on clinical criteria. However, by applying extensive case-finding methods and strict diagnostic criteria and through the availability of additional and long-term data from the computerized follow-up system, we think that diagnostic inaccuracy was reduced as much as possible.
Considering the potential neurotoxicity of homocysteine, 3, 4, 8 we initially hypothesized that higher intakes of folate and vitamins B 12 and B 6 might decrease the risk of PD by decreasing homocysteine levels. We found, indeed, that higher dietary vitamin B 6 was associated with a lower risk of PD. However, no significant association with PD risk was observed for folate and vitamin B 12 . Moreover, higher dietary vitamin B 6 seemed only related to a decreased risk of PD in smokers. Our findings may point toward an alternative mechanism underlying the association for vitamin B 6 intake. Several lines of evidence suggest neuroprotective properties of vitamin B 6 through antioxidant capacities, in addition to decreasing plasma homocysteine. [14] [15] [16] [17] [18] [19] Because oxidative stress may be prominent in PD pathogenesis, 2 higher vitamin B 6 intake may thus reduce PD risk through antioxidant effects. In rats, oxidative stress was induced by vitamin B 6 deficiency 18 and prevented by vitamin B 6 supplementation. 14 Antioxidant activities of vitamin B 6 were also observed in yeast cells, monocytes, and blood plasma. 15, 16, 19 Furthermore, vitamin B 6 is required to convert homocysteine to cysteine, which in turn is the ratelimiting forerunner in the synthesis of glutathione. 19 Reduced levels of glutathione, a major antioxidant, have been found in dopaminergic neurons of PD patients. 2 Pyridoxine also plays a key role in the synthesis of dopamine, because it is a cofactor for dopadecarboxylase, the enzyme needed for the conversion of levodopa to dopamine. 20 Finally, in a recent trial, a significant improvement of mean motor scores was observed in PD patients who received high doses of pyridoxine supplements. 21 An alternative explanation for our findings, therefore, would be that high vitamin B 6 intake does not affect the process of neurodegeneration, but rather just delays the onset of clinical symptoms.
It is unclear why higher vitamin B 6 intake was associated with a decreased risk of PD only in smokers. This is probably accounted for by mutually reinforcing beneficial effects of smoking and vitamin B 6 intake on the risk of PD. Smoking has been associated with a decreased risk of PD in many studies, including the Rotterdam Study, which is believed to be due to neuroprotective effects of nicotine. 28 The relation between dietary folate, vitamin B 12 , and vitamin B 6 and the risk of PD has only been examined in one study previously, in which no significant associations were observed for either of these vitamins. 29 In this US-based prospective study among health professionals, with repeated dietary assessments and case ascertainment based on selfreported diagnoses, median intakes of folate (men 388 g/day, women 277 g/day), vitamin B 12 (men 10.4 g/day, women 6.8 g/day), and vitamin B 6 (men 5.6 mg/day, women 2.3 mg/day) were considerably higher than the corresponding median intakes in the Rotterdam Study (folate: men 223 g/day, women 197 g/day; vitamin B 12 : men 4.7 g/day, women 3.9 g/day; vitamin B 6 : men 1.8 mg/ day, women 1.5 mg/day), probably because of an increased health consciousness among US health professionals, together with the 1998 Food and Drug Administration requirement to fortify grain products with folic acid in the United States. 30 Adequate intake in the US-based study probably precluded demonstrating associations with the risk of PD, which may explain the discrepant findings for vitamin B 6 intake.
Our findings raise the hypothesis that vitamin B 6 may decrease the risk of PD. Alternatively, vitamin B 6 consumption might actually be a marker of other nutrients that are related to PD risk. Besides, a potential effect of folate and vitamin B 12 levels on PD risk is not completely ruled out by our observations on dietary habits. Therefore, to evaluate the association between folate, vitamin B 12 , and vitamin B 6 and the risk of PD, preferably plasma levels of these vitamins would have been studied, which have not been measured in the Rotterdam Study. Our results need confirmation in observational studies or clinical trials that evaluate the relationship between levels of vitamin B 6 and the risk of PD.
